{"groups":[{"description":"Participants received docetaxel 75 milligram per squared meters (mg/m\\^2) administered intravenously on Day 1 of each 21 day cycle until disease progression or unacceptable toxicity or death.","id":"FG000","title":"Docetaxel"},{"description":"Participants were administered atezolizumab intravenously on Day 1 of each 21 day cycle at a fixed dose of 1200 mg. Atezolizumab treatment were to continued as long as participants were experiencing clinical benefit as assessed by the investigator.","id":"FG001","title":"Atezolizumab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"118"},{"groupId":"FG001","numSubjects":"121"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"14"}],"type":"Study Terminated by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"}],"type":"Terminated by Sponsor After 31 Aug 2018"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"143"},{"groupId":"FG001","numSubjects":"144"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"135"},{"groupId":"FG001","numSubjects":"142"}],"comment":"Two patients in the docetaxel arm crossed over to receive atezolizumab treatment.","type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"comment":"Study terminated by Sponsor participants either discontinued or enrolled in extension study","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"143"},{"groupId":"FG001","numSubjects":"144"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 527 participants were screened, of whom 287 participants were randomized. 143 participants to the docetaxel arm and 144 participants to the atezolizumab arm. Overall, 10 participants (8 in the docetaxel arm and 2 in the atezolizumab arm) did not receive any study treatment."}